BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

880 related articles for article (PubMed ID: 17959641)

  • 1. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes.
    Krüger S; Ewig S; Marre R; Papassotiriou J; Richter K; von Baum H; Suttorp N; Welte T;
    Eur Respir J; 2008 Feb; 31(2):349-55. PubMed ID: 17959641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia.
    Müller B; Harbarth S; Stolz D; Bingisser R; Mueller C; Leuppi J; Nusbaumer C; Tamm M; Christ-Crain M
    BMC Infect Dis; 2007 Mar; 7():10. PubMed ID: 17335562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia.
    Zhydkov A; Christ-Crain M; Thomann R; Hoess C; Henzen C; Werner Z; Mueller B; Schuetz P;
    Clin Chem Lab Med; 2015 Mar; 53(4):559-66. PubMed ID: 25014522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of procalcitonin in community-acquired pneumonia.
    Schuetz P; Suter-Widmer I; Chaudri A; Christ-Crain M; Zimmerli W; Mueller B;
    Eur Respir J; 2011 Feb; 37(2):384-92. PubMed ID: 20595156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.
    Krüger S; Ewig S; Giersdorf S; Hartmann O; Suttorp N; Welte T;
    Am J Respir Crit Care Med; 2010 Dec; 182(11):1426-34. PubMed ID: 20639437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ.
    Krüger S; Ewig S; Papassotiriou J; Kunde J; Marre R; von Baum H; Suttor N; Welte T;
    Respir Res; 2009 Jul; 10(1):65. PubMed ID: 19594893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ.
    Krüger S; Papassotiriou J; Marre R; Richter K; Schumann C; von Baum H; Morgenthaler NG; Suttorp N; Welte T;
    Intensive Care Med; 2007 Dec; 33(12):2069-78. PubMed ID: 17938883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia.
    Ugajin M; Yamaki K; Hirasawa N; Yagi T
    Respir Care; 2014 Apr; 59(4):564-73. PubMed ID: 24170911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of biomarkers in differentiating bacterial from non-bacterial lower respiratory tract infection in hospitalized children: difference of the diagnostic performance between acute pneumonia and bronchitis.
    Hoshina T; Nanishi E; Kanno S; Nishio H; Kusuhara K; Hara T
    J Infect Chemother; 2014 Oct; 20(10):616-20. PubMed ID: 25027057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia.
    Schaaf B; Kruse J; Rupp J; Reinert RR; Droemann D; Zabel P; Ewig S; Dalhoff K
    Eur Respir J; 2007 Sep; 30(3):517-24. PubMed ID: 17537775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of procalcitonin level in community-acquired pneumonia in the ED.
    Park JH; Wee JH; Choi SP; Oh SH
    Am J Emerg Med; 2012 Sep; 30(7):1248-54. PubMed ID: 22030193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serial procalcitonin levels for predicting prognosis in community-acquired pneumonia.
    Ito A; Ishida T; Tachibana H; Ito Y; Takaiwa T
    Respirology; 2016 Nov; 21(8):1459-1464. PubMed ID: 27398948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia.
    Menéndez R; Martínez R; Reyes S; Mensa J; Filella X; Marcos MA; Martínez A; Esquinas C; Ramirez P; Torres A
    Thorax; 2009 Jul; 64(7):587-91. PubMed ID: 19131448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of inflammatory markers in patients with community-acquired pneumonia--influence of antimicrobial pre-treatment: results from the German competence network CAPNETZ.
    Krüger S; Ewig S; Kunde J; Hartmann O; Marre R; Suttorp N; Welte T;
    Clin Chim Acta; 2010 Dec; 411(23-24):1929-34. PubMed ID: 20699094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia.
    Christ-Crain M; Breidthardt T; Stolz D; Zobrist K; Bingisser R; Miedinger D; Leuppi J; Tamm M; Mueller B; Mueller C
    J Intern Med; 2008 Aug; 264(2):166-76. PubMed ID: 18298480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of serum procalcitonin and C-reactive protein in severity assessment of community-acquired pneumonia in children.
    Agnello L; Bellia C; Di Gangi M; Lo Sasso B; Calvaruso L; Bivona G; Scazzone C; Dones P; Ciaccio M
    Clin Biochem; 2016 Jan; 49(1-2):47-50. PubMed ID: 26386341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can we predict pneumococcal bacteremia in patients with severe community-acquired pneumonia?
    Pereira JM; Teixeira-Pinto A; Basílio C; Sousa-Dias C; Mergulhão P; Paiva JA
    J Crit Care; 2013 Dec; 28(6):970-4. PubMed ID: 24216331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-reactive protein, procalcitonin, clinical pulmonary infection score, and pneumonia severity scores in nursing home acquired pneumonia.
    Porfyridis I; Georgiadis G; Vogazianos P; Mitis G; Georgiou A
    Respir Care; 2014 Apr; 59(4):574-81. PubMed ID: 24106319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of a semi-quantitative procalcitonin test and the A-DROP Japanese prognostic scale for predicting mortality among adults hospitalized with community-acquired pneumonia.
    Kasamatsu Y; Yamaguchi T; Kawaguchi T; Tanaka N; Oka H; Nakamura T; Yamagami K; Yoshioka K; Imanishi M
    Respirology; 2012 Feb; 17(2):330-6. PubMed ID: 22059525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology.
    Bello S; Lasierra AB; Mincholé E; Fandos S; Ruiz MA; Vera E; de Pablo F; Ferrer M; Menendez R; Torres A
    Eur Respir J; 2012 May; 39(5):1144-55. PubMed ID: 22075489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.